Year: 2024

MONTREAL, Nov. 05, 2024 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ)OPEN TO: Investors, analysts and all interested partiesDATE: Wednesday, November 6, 2024TIME: 10:00 AM Eastern Standard TimeLIVE WEBCAST: https://meetings.lumiconnect.com/400-522-443-288CALL: 1-866-518-4114   THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH GLOBE NEWSWIRE. Please log on or dial in 15 minutes before the conference begins. If you are unable to attend at this time, you may access a web recording of the meeting at the following link: https://meetings.lumiconnect.com/400-522-443-288. This recording will be available on Wednesday, November 6, 2024 as of 1:00 PM EST until 11:59 PM EST on Wednesday, November 13, 2024. MEDIA WISHING TO QUOTE AN ANALYST SHOULD CONTACT THE ANALYST PERSONALLY...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode’s request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D). The listing standards of issue included the bid price requirement in Nasdaq Listing Rule 5550(a)(2); the equity requirement in Listing Rule 5550(b); and Listing Rule 5635(d), concerning shareholder approval of transactions other than public offerings. About...

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call. About Voyager TherapeuticsVoyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics...

During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes. The published data showed that inflammasome NLRP3 inhibition was protective of pancreatic islet beta cells, restoring their function and improving metabolic status in an obesity DIO mouse model. Data from this article support ZyVersa’s development of Inflammasome ASC Inhibitor IC 100 for obesity and its associated comorbidities to be used as an add-on to incretin therapy.WESTON, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical...

MALTA, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) — GlobalFoundries Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2024. Key Third Quarter Financial HighlightsRevenue of $1.739 billion Gross margin of 23.8% and Non-IFRS gross margin(1) of 24.7% Operating margin of 10.6% and Non-IFRS operating margin(1) of 13.6% Net income of $178 million and Non-IFRS net income(1) of $229 million Non-IFRS adjusted EBITDA(1) of $627 million Cash, cash equivalents and marketable securities of $4.3 billion Year to date net cash provided by operating activities of $1,265 million and Non-IFRS adjusted free cash flow(1) of $779 million“In the third quarter, the GF team continued to execute next generation opportunities with our customers, by securing key design wins across our growing...

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024. The fireside chat is scheduled for Tuesday, November 19, 2024, at 1:50 p.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/. About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating...